Loading clinical trials...
Loading clinical trials...
The Effects of ATLAS (Arginine Tetrahydrobiopterin L-Ascorbate) Therapy on Nitric Oxide Bioavailability and Pain-free Walking in Patients With Intermittent Claudication
Conditions
Interventions
Tetrahydrobiopterin 10 mg/kg
Tetrahydrobiopterin 20 mg/kg
+2 more
Locations
1
United States
UMASS Memorial Healthcare - University Campus
Worcester, Massachusetts, United States
Start Date
June 15, 2021
Primary Completion Date
July 1, 2027
Completion Date
December 1, 2027
Last Updated
April 15, 2026
NCT05624125
NCT06212271
NCT07283289
NCT06656988
NCT06003855
NCT05628948
Lead Sponsor
Louis Messina
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions